S&P 500
7,452.80
+1.29%
Dow Jones
52,297.10
+0.68%
Nasdaq 100
29,800.30
+2.47%
Russell 2000
3,009.35
+0.14%
FTSE 100
10,540.20
+0.33%
Nikkei 225
70,654.80
+1.37%
Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ) Q1 2026 Earnings

Reported May 5, 2026 at 4:06 PM ET · SEC Source

Q1 26 EPS

$6.34

BEAT +36.18%

Est. $4.66

Q1 26 Revenue

$1.07B

BEAT +9.18%

Est. $979.0M

vs S&P Since Q1 26

+5.1%

BEATING MARKET

JAZZ +6.1% vs S&P +1.0%

Market Reaction

Did JAZZ Beat Earnings? Q1 2026 Results

Jazz Pharmaceuticals delivered a standout first quarter for fiscal 2026, posting non-GAAP adjusted EPS of $6.34 against a consensus estimate of $4.66, a beat of 36.18%, while revenue climbed 19.1% year-over-year to $1.07 billion, exceeding analyst ex… Read more Jazz Pharmaceuticals delivered a standout first quarter for fiscal 2026, posting non-GAAP adjusted EPS of $6.34 against a consensus estimate of $4.66, a beat of 36.18%, while revenue climbed 19.1% year-over-year to $1.07 billion, exceeding analyst expectations of $979.01 million by 9.18%. The headline driver behind the earnings strength was broad commercial momentum across the company's core franchises, with Xywav contributing $408.20 million as the largest single revenue source, Epidiolex growing 15% to $249.80 million, and Zepzelca surging 60% to $101.00 million on the strength of its atezolizumab combination in small cell lung cancer. A $122.80 million gain from the sale of a Rare Pediatric Disease Priority Review Voucher further supported GAAP results, helping swing net income to $293.10 million from a loss of $92.50 million a year ago. Shares reached notable highs in the wake of the report, reflecting investor confidence in Jazz's diversified portfolio. Management reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.50 billion, with a potential zanidatamab approval in gastroesophageal adenocarcinoma carrying a PDUFA date of August 25, 2026.

Key Takeaways

  • • Strong Xywav demand with 425 net patient adds reaching ~16,600 active patients
  • • Zepzelca revenues grew 60% YoY driven by uptake of Zepzelca and atezolizumab combination in 1LM ES-SCLC
  • • Epidiolex continued consistent demand-driven growth of 15% YoY
  • • Modeyso contributed $41 million in its first full quarter following August 2025 launch
  • • SG&A declined significantly due to $172 million Xyrem antitrust litigation settlements in 1Q25 not recurring
  • • $122.8 million gain on sale of Priority Review Voucher

JAZZ Forward Guidance & Outlook

Jazz Pharmaceuticals reaffirmed its full-year 2026 revenue guidance of $4,250 million to $4,500 million. The company also reaffirmed expense guidance: GAAP gross margin of 89%-90%, GAAP SG&A of $1,424-$1,497 million, GAAP R&D of $811-$867 million, and GAAP effective tax rate of 0%-10%. Non-GAAP gross margin is guided at 90%-91%, non-GAAP SG&A of $1,260-$1,320 million, non-GAAP R&D of $725-$775 million, and non-GAAP effective tax rate of 11.5%-13.5%. Weighted-average shares outstanding guidance was updated to 66-67 million. The company expects second-line Zepzelca use to decline throughout the year. The zanidatamab sBLA in 1L HER2+ GEA has a PDUFA date of August 25, 2026, with potential approval and launch on or before that date. The Phase 3 ACTION trial for Modeyso has a top-line readout expected late 2026/early 2027.

24/7 Wall St

JAZZ YoY Financials

Q1 2026 vs Q1 2025, source: SEC Filings

24/7 Wall St

JAZZ Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026.”

— Renee Gala, Q1 2026 Earnings Press Release

Back to JAZZ Stock Page